Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Jul 15, 2023
TickeronGET DAILY SIGNALS
Boost Day Trading with OCGN: High-Volatility Stock strong performance

Boost Day Trading with OCGN: High-Volatility Stock strong performance

Day Trader: High Volatility Stocks for Active Trading (TA&FA) Generate 13.73% for OCGN

OCGN, an engaging target for day traders, has recently shown significant movement in the market, generating a strong performance. This stock has proven to be a compelling asset in active trading, particularly due to its high volatility, making it a particularly suitable candidate for traders who thrive in dynamic market conditions.

Notably, OCGN's Moving Average Convergence Divergence (MACD) histogram just turned positive on June 12, 2023. This is an intriguing development for day traders who rely on this indicator as a valuable tool for spotting potential buying opportunities. A positive MACD often indicates an upward price trend, meaning the stock may offer promising returns.

Historical analysis of OCGN further strengthens this prediction. Past records show that whenever the MACD for OCGN turned positive, the stock continued to rise in 47 out of 52 cases over the following month. This translates to an impressive success rate of approximately 90%.

These figures reflect the potential robustness of using the MACD as an indicator for buying opportunities with OCGN. The historical consistency of the stock's positive response to a positive MACD histogram underlines the potential for continued growth in the short term.

The high volatility of OCGN combined with its recent positive MACD provides an exciting proposition for day traders. These traders can potentially benefit from both the rapid price swings inherent in high-volatility stocks and the predictive power of a positive MACD.

OCGN is a stock that day traders should consider monitoring closely, given its high volatility and the recent positive shift in its MACD. As historical trends suggest, there's a significant chance that OCGN will continue to provide robust returns, making it an attractive option for active trading.

Related Ticker: OCGN

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


OCGN in -9.49% downward trend, sliding for three consecutive days on October 30, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OCGN declined for three days, in 292 of 329 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

OCGN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for OCGN entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OCGN's RSI Indicator exited the oversold zone, 30 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on OCGN as a result. In 75 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for OCGN just turned positive on November 02, 2026. Looking at past instances where OCGN's MACD turned positive, the stock continued to rise in 45 of 55 cases over the following month. The odds of a continued upward trend are 82%.

Following a +20.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where OCGN advanced for three days, in 186 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-18.946) is normal, around the industry mean (3.498). P/E Ratio (-3.558) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (70.423) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. OCGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 85%. LABT experienced the highest price growth at 126%, while ZURA experienced the biggest fall at -69%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 0%. For the same stocks of the Industry, the average monthly volume growth was 0% and the average quarterly volume growth was -46%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the development and commercialization of therapies for eye diseases

Industry Biotechnology

Industry
N/A
Address
11 Great Valley Parkway
Phone
+1 484 328-4701
Employees
116
Web
https://www.ocugen.com
Interact to see
Advertisement
SAN is Spain's largest bank with a diversified footprint across Europe and the Americas, while SMFG is Japan's second-largest lender anchored in a resurgent domestic banking market. Both names are riding structural tailwinds: SAN from efficiency gains and U.S./UK acquisitions, and SMFG from the Bank of Japan's rate-hiking cycle and the end of deflation.
RAPP fell -9.23% to about $26.66 during regular trading on Oct. 21, down from the prior close of $29.37. The decline unwinds Monday's brief post-trial pop as investors keep reassessing the Phase 2 RAP-219 bipolar mania results.
The central stock price target of $100 is the arithmetic mean of the verified analyst price targets reviewed; major aggregators report a similar consensus near $99–$102, with a wide range from roughly $60 to $150. With the stock trading near $53, reaching $100 would require a gain of approximately 88% — a very large move from current levels.
NVDA dropped from Friday's close of $186.64 to $174.06 intraday, down -6.74%, during regular market hours. The slide followed CEO Jensen Huang's admission of an extramarital affair and the board's independent investigation, announced November 8, after reports he was targeted by a suspected Chinese intelligence operative.
NFT Limited (MI) rebounded +21.35% during regular market hours, trading near $1.08 versus the prior session's $0.89 close. The gain follows a steep -41.89% plunge the prior session after the company priced a dilutive 1 million-unit direct offering at $1.00 per unit.
Boost Day Trading with OCGN: High-Volatility Stock strong performance